Abstract
Abstract
Background
Preventative inhaled treatments preserve lung function and reduce exacerbations in cystic fibrosis (CF). Self-reported adherence to these treatments is over-estimated. An online platform (CFHealthHub) has been developed with patients and clinicians to display real-time objective adherence data from dose-counting nebulisers, so that clinical teams can offer informed treatment support.
Methods
In this paper, we identify pre-implementation barriers to healthcare practitioners performing two key behaviours: accessing objective adherence data through the website CFHealthHub and discussing medication adherence with patients. We aimed to understand barriers during the pre-implementation phase, so that appropriate strategy could be developed for the scale up of implementing objective adherence data in 19 CF centres.
Thirteen semi-structured interviews were conducted with healthcare practitioners working in three UK CF centres. Qualitative data were coded using the theoretical domains framework (TDF), which describes 14 validated domains to implementation behaviour change.
Results
Analysis indicated that an implementation strategy should address all 14 domains of the TDF to successfully support implementation. Participants did not report routines or habits for using objective adherence data in clinical care. Examples of salient barriers included skills, beliefs in consequences, and social influence and professional roles. The results also affirmed a requirement to address organisational barriers. Relevant behaviour change techniques were selected to develop implementation strategy modules using the behaviour change wheel approach to intervention development.
Conclusions
This paper demonstrates the value of applying the TDF at pre-implementation, to understand context and to support the development of a situationally relevant implementation strategy.
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. Charman, Susan, McClenaghan, Elliot, Cosgriff, Rebecca, Lee, Andrew, Carr S. UK Cystic Fibrosis Registry Annual data report 2018 2019. https://www.cysticfibrosis.org.uk/sites/default/files/2020-12/2018. Accessed 11 May 2021.
2. Agent P, Parrott H. Inhaled therapy in cystic fibrosis: agents, devices and regimens. Breathe. 2015;11:111–8.
3. Southern KW, Barker PM, Solis-Moya A, et al. Macrolide antibiotics for cystic fibrosis. In: Southern KW, editor. Cochrane Database of Systematic Reviews. Chichester: Wiley; 2011. Epub ahead of print December 2011. https://doi.org/10.1002/14651858.CD002203.pub3.
4. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England J Med. 2011;365(18):1663–72.
5. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9):921–8.